ChiCTR2300068084
尚未开始
/
/
/
2023-02-06
/
/
Long COVID-19 symptoms
Effects of stand-alone mindfulness practices for people with long COVID-19 symptoms: A randomized controlled trial
Effects of stand-alone mindfulness practices for people with long COVID-19 symptoms: A randomized controlled trial
This study aims to evaluate the effects of mindfulness practices as a standalone intervention (an 8-week 1.25-hour online mindfulness practices class led by a mindfulness teacher, together with practice audios and a self-help booklet) among people with long COVID-19 symptoms, comparing to a health education control through a randomized controlled trial design. The primary objective is to: 1. Evaluate the effectiveness of the mindfulness practices in improving self-reported severity of long COVID-19 symptoms, functional disability, and overall health immediately after the 8-week intervention (primary time point) and 3 months after the intervention, comparing to the health education control. The secondary objectives are to: 2. Evaluate the effectiveness of the mindfulness practices in reducing proportions of participants having 1+, 3+, and 5+ symptoms in the intervention group immediately and 3 months after the 8-week intervention, compared to the control. 3. Evaluate the effectiveness of mindfulness practices in reducing depression, anxiety, health care utilization, and improving mindfulness and health-related quality of life immediately and 3 months after the intervention, compared to the control.
随机平行对照
其它
Computer-based simple randomization will be applied. The randomization procedure will be conducted by an independent statistician who is experienced in conducting randomization.
Participants will be asked not to disseminate the intervention contents during the study period to prevent contamination between the intervention and control groups. Due to the nature of the intervention, it is impossible to blind therapists and participants, but the investigators and persons who conduct the statistical analyses will be blinded to treatment allocation.
Health and Medical Research Fund, Food and Health Bureau, HKSAR
/
165
/
2023-02-06
2025-02-05
/
Inclusion criteria: 1. Aged 18 years or above, 2. With any self-reported long COVID-19 symptoms listed in the recent systematic review by Michelen and colleagues at least 3 months after tested positive for COVID-19, either through self-test or test in medical settings: (1) Systematic symptoms (fatigue, weakness, general malaise, dizziness); (2) Cardiopulmonary symptoms (breathlessness/dyspnoea, chest pain, cough, excessive sputum, others); (3) Upper respiratory symptoms (voice change, sore throat, nasal congestion, others), (4) Gastrointestinal symptoms (loss of appetite, stomach/abdominal discomfort/pain, weight loss, nausea or vomiting, diarrhoea, others); (5) Musculoskeletal symptoms (muscle pain/myalgia, joint pain/arthralgia, impaired mobility, others); (6) Neurological and neuromuscular symptoms (abnormal reflex status, smell disturbance, taste disturbance, decreased sensation or sensibility, tingling/ paraesthesia, others); (7) Neurocognitive symptoms (memory impairment, concentration impairment, frontal release signs, others), or others (hair loss, skin rash etc.) 3. No regular practice of mindfulness meditation.；
登录查看Exclusion criteria: 1. Diagnosed psychiatric disorders, and suicidal ideation, plans, or behaviours, as they may need more intensive clinical care; 2. Recent bereavement or major loss; 3. Cannot understand Chinese as the programs will be conducted in Chinese; 4. Other conditions render them incapable of following the interventions.；
登录查看JC School of Public Health and Primary Care, The Chinese University of Hong Kong
/
精准药物2024-11-22
亚泰制药2024-11-22
医药时间2024-11-21
一度医药2024-11-21
新药创始人2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
药时空2024-11-21
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
